(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
This professional Santa's dream of spreading holiday cheer fuels stroke recovery - 2Taylor Frankie Paul's domestic violence case is fueling discussions about DARVO. Experts say terms like this shouldn't be used lightly.
- 3Instructions to Upgrade the Security Elements of Your Kona SUV
- 4How to avoid or deal with an outrageous medical bill
- 5Hamas propaganda expert explains Israel's internal conflicts influenced Hamas's Oct. 7 assault
- Clovis Unified students spend spring break traveling through China
- New nesting beach for birds at RSPB reserve
- The Electric Toyota Hilux Is Finally here, But It's Not Cheap
- Deadly Switzerland ski resort fire was likely started by sparklers attached to champagne bottles, officials say
- UK forecast to face weaker growth and higher inflation from Iran war
- German gas price bill signed into law, but consumers not impressed
- Exploring Asia’s Realm of Flying Snakes
- Top 15 Style Creators Changing the Business
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
